CONMED (NYSE:CNMD) versus Beyond Air (NASDAQ:XAIR) Financial Contrast

Beyond Air (NASDAQ:XAIR) and CONMED (NYSE:CNMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.

Earnings & Valuation

This table compares Beyond Air and CONMED”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beyond Air	$7.68 million	0.40	-$33.25 million	($68.40)	-0.05
CONMED	$1.37 billion	1.01	$47.06 million	$1.85	24.95

CONMED has higher revenue and earnings than Beyond Air. Beyond Air is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

31.5% of Beyond Air shares are held by institutional investors. 10.0% of Beyond Air shares are held by insiders. Comparatively, 0.3% of CONMED shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Beyond Air and CONMED, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beyond Air	1	0	3	0	2.50
CONMED	2	6	0	0	1.75

Beyond Air currently has a consensus target price of $105.00, suggesting a potential upside of 3,181.25%. CONMED has a consensus target price of $41.40, suggesting a potential downside of 10.29%. Given Beyond Air’s stronger consensus rating and higher possible upside, research analysts plainly believe Beyond Air is more favorable than CONMED.

Profitability

This table compares Beyond Air and CONMED’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beyond Air	-435.71%	-440.26%	-98.50%
CONMED	4.12%	14.31%	6.33%

Volatility & Risk

Beyond Air has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, CONMED has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

Summary

CONMED beats Beyond Air on 9 of the 14 factors compared between the two stocks.

About Beyond Air

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.